LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.

@article{Alghamdi2015LDLRPA,
  title={LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.},
  author={Rasha H Alghamdi and Paul O'reilly and Chunyu Lu and James Gomes and Thomas A. Lagace and Amit Basak},
  journal={European journal of medicinal chemistry},
  year={2015},
  volume={92},
  pages={890-907}
}
BACKGROUND High level of Low Density Lipoprotein-Cholesterol (LDL-C) in circulation in the blood is associated with an elevated risk of cardiovascular disease (CVD) and stroke. Currently the statin drugs which inhibit the enzyme HMG-CoA reductase responsible for cholesterol synthesis in the liver are very effective in lowering LDL-cholesterol. However these drugs are often associated with serious side effects particularly for ∼10-12% of cases. Therefore there is a need to develop non-statin… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 85 references

Cell sensi tivity assays: the MTT assay

  • J van Meerloo, GJ Kaspers, J. Cloos
  • Methods Mol Biol
  • 2011
Highly Influential
5 Excerpts

In vitro regulatory effects of epidydimal serpin CRES on protease activity of P roprotein Convertase 4 (PC4)

  • Mishra, Q P Qing, A Gruslin, Y Hidaka, M Mbikay, A. Basak
  • Current Molecular Medicine
  • 2012
Highly Influential
4 Excerpts

A PCSK9binding antibody that structurally mimics the EGF(A ) domain of LDL-receptor reduces LDL cholesterol in vivo

  • YG Ni, S Di Marco, +27 authors A. Sitlani
  • J Lipid Res
  • 2011
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…